Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.
暂无分享,去创建一个
Sunil V. Rao | S. Pocock | T. Henry | S. Kapadia | J. Muhlestein | M. Effron | R. Mehran | W. Weintraub | A. Kini | U. Baber | B. Vogel | B. Claessen | S. Sartori | J. Chandrasekhar | M. Faggioni | M. Aquino | Sandra A. Weiss | C. Strauss | C. Toma | A. Defranco | S. Keller | B. Baker | S. Sorrentino | S. Farhan | Clayton Snyder | K. Poddar | C. Snyder | S. Rao
[1] S. Pocock,et al. Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study , 2017, American heart journal.
[2] G. Heinze,et al. Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. , 2017, International journal of cardiology.
[3] Samin K. Sharma,et al. Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. , 2017, The American journal of cardiology.
[4] S. Pocock,et al. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. , 2017, JACC. Cardiovascular interventions.
[5] G. Filardo,et al. Long Term Efficacy of Prasugrel versus Clopidogrel in Patients undergoing Percutaneous Coronary Intervention and Anticoagulated with Bivalirudin , 2016 .
[6] Deepak L. Bhatt,et al. Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. , 2016, American heart journal.
[7] J. Rumsfeld,et al. Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program , 2016, Clinical Cardiology.
[8] T. Engstrøm,et al. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response – The TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial , 2014, Platelets.
[9] Eric D. Peterson,et al. Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry , 2014, Journal of the American Heart Association.
[10] A. Majluf-Cruz,et al. Proinflammatory and Prothrombotic State in Subjects with Different Glucose Tolerance Status before Cardiovascular Disease , 2014, Journal of diabetes research.
[11] H. Gurm,et al. Contemporary Use of Prasugrel in Clinical Practice: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium , 2013, Circulation. Cardiovascular quality and outcomes.
[12] C. Terkelsen,et al. Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. , 2012, The American journal of cardiology.
[13] S. Stevens,et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial , 2010, European heart journal.
[14] Christopher P Cannon,et al. Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.
[15] D. Angiolillo,et al. A Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease : The OPTIMUS ( Optimizing Antiplatelet Therapy in Diabetes Mellitus )-4 Study , 2016 .